GS JT (Votrient pazopanib 200 mg)

Generic Name: pazopanib

Pill imprint GS JT has been identified as Votrient pazopanib 200 mg.

Votrient is used in the treatment of renal cell carcinoma; soft tissue sarcoma and belongs to the drug class VEGF/VEGFR inhibitors. There is positive evidence of human fetal risk during pregnancy. Votrient pazopanib 200 mg is not subject to the Controlled Substances Act.

See also related documents.

Imprint Search

Images for GS JT

Votrient pazopanib 200 mg GS JT
Votrient
Generic Name:
pazopanib
Imprint:
GS JT
Strength:
pazopanib 200 mg
Color:
Gray
Size:
14.00 mm
Shape:
Capsule-shape
Availability:
Prescription only
Drug Class:
VEGF/VEGFR inhibitors
Pregnancy Category:
D - Positive evidence of risk
CSA Schedule:
N - Not a controlled drug
Manufacturer:
GlaxoSmithKline
National Drug Code (NDC):
00173-0804
Inactive Ingredients:
magnesium stearate
microcrystalline cellulose
povidone
sodium starch glycolate type A potato
hypromelloses
ferrosoferric oxide
polyethylene glycol 400
polysorbate 80
titanium dioxide

View Details Print Page

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2014 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide
(web5)